Treatment and primary prevention in people who inject drugs for chronic hepatitis C infection: is elimination possible in a high-prevalence setting?

ABSTRACT:

Aims

To project the impact of scaling-up oral anti-viral therapy and harm reduction on chronic hepatitis C (CHC) prevalence and incidence among people who inject drugs (PWID) in Greece, to estimate the relationship between required treatment levels and expansion of harm reduction programmes to achieve specific targets and to examine whether hepatitis C virus (HCV) elimination among PWID is possible in this high-prevalence setting.

Design

A dynamic discrete time, stochastic individual-based model was developed to simulate HCV transmission among PWID incorporating the effect of HCV treatment and harm reduction strategies, and allowing for re-infection following treatment.

Setting/participants

The population of 8300 PWID in Athens Metropolitan area.

Measurements

R

SUBMITTER: Gountas I 

PROVIDER: S-EPMC5553636 | biostudies-literature | 2017 Jul

REPOSITORIES: biostudies-literature